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In Brief
Highly malignant primitive
neuroectodermal tumors of the CNS
(CNS-PNETs) have been challenging to
diagnose and distinguish from other
kinds of brain tumors, but molecular
profiling now reveals that these cancers
can be readily classified into some known
tumor types and four new entities with
distinct histopathological and clinical
features, paving the way for meaningful
clinical trials.Accession NumbersGSE73038
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(Affiliations continued on next page)SUMMARY
Primitive neuroectodermal tumors of the central ner-
vous system (CNS-PNETs) are highly aggressive,
poorly differentiated embryonal tumors occurring
predominantly in young children but also affecting
adolescents and adults. Herein, we demonstrate
that a significant proportion of institutionally diag-
nosed CNS-PNETs display molecular profiles
indistinguishable from those of various other well-
defined CNS tumor entities, facilitating diagnosis
and appropriate therapy for patients with these tu-
mors. From the remaining fraction of CNS-PNETs,
we identify four new CNS tumor entities, each asso-
ciated with a recurrent genetic alteration and distinct
histopathological and clinical features. These new1060 Cell 164, 1060–1072, February 25, 2016 ª2016 Elsevier Inc.molecular entities, designated ‘‘CNS neuroblastoma
with FOXR2 activation (CNS NB-FOXR2),’’ ‘‘CNS
Ewing sarcoma family tumor with CIC alteration
(CNS EFT-CIC),’’ ‘‘CNS high-grade neuroepithelial
tumor with MN1 alteration (CNS HGNET-MN1),’’
and ‘‘CNS high-grade neuroepithelial tumor with
BCOR alteration (CNS HGNET-BCOR),’’ will enable
meaningful clinical trials and the development of
therapeutic strategies for patients affected by poorly
differentiated CNS tumors.
INTRODUCTION
TheCNS comprisesmany different pluripotent and differentiated
cell types that vary greatly in abundance during human lifespan.
This is reflected by a broad diversity of CNS tumor entities, some
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(Affiliations continued on next page)of which are relatively common, whereas others develop rarely,
and many of them occur at defined ages. Primitive neuroecto-
dermal tumors of the CNS (CNS-PNETs) are highly malignant
neoplasms that predominantly affect children but may also arise
in adolescents and adults. Histologically, CNS-PNETs are char-
acterized by small, poorly differentiated or undifferentiated
embryonal cells with a propensity for both glial and neuronal dif-
ferentiation (Louis et al., 2007), but the neuropathological diag-
nosis is challenging due to a lack of defining molecular markers
and histological overlap with other high-grade neuroepithelial tu-
mors. The original concept related medulloblastoma (i.e., PNET
of the cerebellum) to embryonal tumors of the cerebrum (supra-tentorial PNET) (Rorke, 1983), but issues with the clinicopatho-
logical utility of classifying non-cerebellar CNS-PNETs have
generated significant controversy over decades (Rorke et al.,
1997). This resulted in considerable uncertainty regarding accu-
rate diagnosis and optimal treatment for affected patients (Ja-
kacki et al., 2015). The 2007 World Health Organization (WHO)
classification of CNS tumors lists CNS-PNETNOS (not otherwise
specified) and four histological CNS-PNET variants distin-
guished by morphological features: CNS neuroblastoma, CNS
ganglioneuroblastoma, medulloepithelioma (ME), and ependy-
moblastoma (EB) (Louis et al., 2007). Embryonal tumors with
abundant neuropil and true rosettes (ETANTR) have beenCell 164, 1060–1072, February 25, 2016 ª2016 Elsevier Inc. 1061
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http://dx.doi.org/10.1016/j.cell.2016.01.015recognized as a histological variant without a specific designa-
tion. The identification of focal amplification of amicro-RNA clus-
ter on 19q13.42 (C19MC) as a unifying feature of ME, EB, and
ETANTR (Eberhart et al., 2000; Korshunov et al., 2010, 2014; Li
et al., 2009; Spence et al., 2014) led to the recognition of an
overarching molecular and clinicopathological entity of embry-
onal tumors with multi-layered rosettes (ETMR, C19MC-altered)
in the next revision of the WHO classification, adding to a
growing list of definingmolecular aberrations in high-grade pedi-
atric CNS tumors (Capper et al., 2010; Chan et al., 2013; Hassel-
blatt et al., 2013; Margol and Judkins, 2014; Pajtler et al., 2015;
Parker et al., 2014; Schneppenheim et al., 2010; Schwartzen-
truber et al., 2012; Venneti et al., 2013; Wu et al., 2012; Yan
et al., 2009).
Recent studies support the notion that CNS-PNETs represent
a molecularly heterogeneous group of tumors (Danielsson et al.,1062 Cell 164, 1060–1072, February 25, 2016 ª2016 Elsevier Inc.2015; Picard et al., 2012; Schwalbe et al., 2013), indicating an ur-
gent need for better methods of classification. To provide a
better framework for accurate diagnosis and treatment, we per-
formed a comprehensive molecular characterization of a large
cohort of institutionally diagnosed CNS-PNETs, aiming to fully
elucidate their underlying molecular and biological spectrum.
RESULTS
DNA Methylation Profiling of CNS-PNETs
We generated genome-wide DNAmethylation profiles of 323 tu-
mors with an institutional diagnosis of ‘‘CNS-PNET.’’ Unsuper-
vised clustering, including 211 well-characterized ‘‘reference’’
tumors representing other CNS tumor entities, reliably separated
samples into clusters defined by histological entities and known
molecular subgroups (Figures 1A, 1B, and S1A–S1D; Table S1).
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Figure 1. Molecular Classification of CNS-PNETs by DNA Methylation Profiling
(A) Unsupervised clustering of DNA methylation patterns of 323 CNS-PNET samples alongside 211 reference samples representing CNS tumors of known
histology andmolecular subtype using the 10,000most variably methylated probes. Molecular diagnostic reference tumors or CNS-PNETs (inner circle) and gene
expression subgroup assignment (outer circle) are depicted by colored bars as indicated. DNA methylation clusters are highlighted by colors as indicated. Gray
bars indicate samples unclassifiable by gene expression analyses.
(B) 2D representation of pairwise sample correlations using the 10,000 most variably methylated probes by t-distributed stochastic neighbor embedding (tSNE)
dimensionality reduction. The same samples as in (A) are used (n = 534). Reference samples are colored according to their molecular reference entity. CNS-PNET
samples are colored in black. Lines connect each sample to the centroid of its respective molecular CNS tumor entity.
(C) Re-classification of 323 CNS-PNETs into known molecular reference entities and four new CNS tumor entities by molecular profiling. Entities correspond to
DNA methylation clusters and are represented by colors as indicated.
See also Figure S1 and Table S1.CNS-PNETs did not form a distinct cluster, but mostly grouped
with clusters of reference CNS tumors. In total, 196/323 (61%)
of CNS-PNETs clustered with ETMRs (36/323, 11%), MYCN-
amplified high-grade gliomas (HGGMYCN, 28/323, 9%), IDH/
H3F3A wild-type HGG from receptor tyrosine kinase (RTK) sub-
groups (HGGRTK, 28/323, 9%), IDH mutant HGG (HGGIDH,
17/323, 5%), H3F3A G34 mutant HGG (HGGG34, 17/323, 5%),
supratentorial ependymomas (EPN, 15/323, 5%), AT/RTs
(14/323, 4%), H3F3A K27 mutant diffuse midline gliomas
(HGGK27, 10/323, 3%), pineal tumors (PIN, 8/323, 2%), Ewingsarcomas (EWS, 5/323, 2%), choroid plexus carcinomas
(CPC, 2/323, 1%), pleomorphic xanthoastrocytomas (PXA,
1/323, <1%), or meningiomas (MNG, 1/323, <1%) (Figures 1A–
1C, S1A, and S1B). SomeCNS-PNETs also grouped withmedul-
loblastoma subtypes (MBWNT, MBSHH, MBGrp3, MBGrp4, 11/323,
3%), including one metastasis of a primary brainstem lesion with
PNET histology. However, available radiological reports of these
MB-like cases did not indicate a cerebellar lesion. Three further
samples (1%) clustered with non-neoplastic hemispheric brain
tissue samples, suggesting high normal cell content.Cell 164, 1060–1072, February 25, 2016 ª2016 Elsevier Inc. 1063
Some of the remaining CNS-PNETs (50/323, 15%) formed
small, inhomogeneous clusters (<5 tumors) or represented
distant outliers that failed to group with each other or any of
the reference tumor entities, possibly representing exceedingly
rare entities. A larger fraction of remaining CNS-PNETs (77/
323, 24%) formed four separate clusters clearly distinct from
reference entities. As elucidated below, these represent four
new CNS tumor entities that we termed ‘‘CNS neuroblastoma
with FOXR2 activation’’ (CNS NB-FOXR2; 44/323, 14%), ‘‘CNS
Ewing sarcoma family tumor with CIC alteration’’ (CNS EFT-
CIC; 12/323, 4%), ‘‘CNS high-grade neuroepithelial tumor with
MN1 alteration’’ (CNS HGNET-MN1; 11/323, 3%), and ‘‘CNS
high-grade neuroepithelial tumor with BCOR alteration’’ (CNS
HGNET-BCOR; 10/323, 3%). Unsupervised clustering restricted
to CNS-PNET samples recapitulated cluster associations estab-
lished in the overall analysis (Figures S1C and S1E). For a subset
of tumors (109 reference samples; 59 CNS-PNET), transcrip-
tomic profiling allowed assignment into gene expression-based
subgroups that correlated well with DNA methylation clusters
(Figures 1A, S1A, and S1F).
Re-classification of CNS-PNETs into Other CNS Tumor
Entities
To validate the re-classification of CNS-PNETs sharing concor-
dant DNAmethylation and transcriptomic profiles with reference
tumor entities,we analyzed these samples for hallmarkmolecular
features previously established for their assigned reference tu-
mor entities. Only CNS-PNET samples from the ETMR cluster
consistently harbored the C19MC amplicon (33/36, 92% of
samples with available data; p < 0.001) and displayed high
LIN28A protein expression (17/17, 100%; p < 0.001), which has
been proposed as a potent diagnostic marker for ETMR (Korshu-
nov et al., 2012, 2014; Spence et al., 2014) (Figure 2A). All
analyzed CNS-PNET samples from the AT/RT cluster displayed
SMARCB1 mutations and/or deletions (14/14, 100%; p < 0.001)
and loss of the SMARCB1 protein product INI-1 (5/5, 100%;
p< 0.001) (Figure 2B). Targeted sequencing confirmedmutations
in IDH1 in 15/15 CNS-PNETs (100%; p < 0.001) from the HGGIDH
cluster, G34 mutations of H3F3A in 17/17 CNS-PNETs (100%;
p < 0.001) from the HGGG34 cluster, and K27 mutations of
H3F3A in 4/7 CNS-PNETs (57%; p < 0.001) from the HGGK27
cluster (Figure 2C). Within the HGGMYCN cluster, 20/28 CNS-
PNETs (71%; p < 0.001) displayed amplification of theMYCN lo-
cus (Figure 2D).Co-amplification ofMYCNand ID2wasobserved
in 12/28 (43%; p < 0.001) samples, therefore broadening a previ-
ously defined molecular subgroup of diffuse intrinsic pontine gli-
omas (DIPG) to include supratentorial tumors with HGG or PNET
histopathology (Buczkowicz et al., 2014). Where tested by fluo-
rescence in situ hybridization (FISH; 4/4), MYCN and ID2 were
co-amplified in the same tumor cell nuclei (Figure 2D). CNS-
PNETs within the HGGRTK clusters showed diverse, broad chro-
mosomal copy-number alterations, and half (14/28, 50%)
harbored focal amplifications and/or deletions of known onco-
genes and/or tumor suppressor genes (Figures S2A and S2B).
In the three CNS-PNETs from the EWS cluster, the presence of
a EWSR1 re-arrangement was detected by RNA sequencing or
FISH analysis (data not shown). There was insufficient material
to investigate CNS-PNETs from the EPN clusters for the pres-1064 Cell 164, 1060–1072, February 25, 2016 ª2016 Elsevier Inc.ence of RELA or YAP1 fusions. Patient information (age at
diagnosis, tumor location, and survival) of CNS-PNETs from
aforementioned clusters matched clinical features of their refer-
ence entities and subgroups (Figures 2E–2H and S2C–S2G).
Where available, the histology of CNS-PNETs with DNA
methylation profiles and molecular markers associated with
other CNS tumor entities (n = 71) was re-evaluated by an expert
panel of neuropathologists. In most instances, the tumors
demonstrated histological features either supporting their mo-
lecular re-classification or ambiguous histology for which the en-
tity suggested by the molecular re-classification would be
included in the differential diagnosis (Tables S2A–S2C). Among
the tumors re-classified into other CNS tumor entities were
small-cell tumors displaying classic features attributed to CNS-
PNET (Figures S2H–S2M). These features were not restricted
to the ETMR group but were also prominent in the HGGG34
andHGGMYCN groups, in which specific examples demonstrated
hallmark features of anaplasia, including cell wrapping and
prominent nucleoli, while other tumors demonstrated diffuse
infiltrative growth more typical of HGG. Rare examples of tumors
re-classified into a HGG group demonstrated robust neuronal
antigen expression, highlighting the insufficiency of glial and
neuronal antigen expression alone to reliably discriminate these
malignant small-cell CNS tumors (Figures S2N–S2P).
Identification of Four New Molecular CNS Tumor
Entities
Our initial clustering analysis of CNS-PNETs identified four new
molecular entities designated ‘‘CNS NB-FOXR2,’’ ‘‘CNS EFT-
CIC,’’ ‘‘CNS HGNET-MN1,’’ and ‘‘CNS HGNET-BCOR.’’ To
explore whether these molecular entities were also diagnosed
other than CNS-PNET, we compared DNA methylation patterns
of each entity with an in-house collection of >10,000 profiles
from a broad variety of pediatric and adult CNS tumors (data
not shown). Subsequent clustering analysis identified 59
tumors with diverse histological diagnoses that now grouped
with one of the four new CNS tumor entities (Figures 3A, 3B,
and S3A–S3C; Table S3). While the enlarged CNS NB-FOXR2
(n = 46) and CNS EFT-CIC (n = 15) clusters represented entities
with almost exclusive CNS-PNET histology (Figures 3A and 3B),
the CNS HGNET-MN1 cluster (n = 41) included 16 tumors histo-
logically diagnosed as astroblastoma (ABM)—rare WHO-
defined glial tumors—supporting the concept that they are
distinct from conventional diffuse glial neoplasms (Louis et al.,
2007). The CNS HGNET-BCOR cluster (n = 34) was expanded
by a variety of CNS tumor histologies. Again, molecular sub-
group assignment by transcriptomic profiling recapitulated
DNA methylation-based clusters (Figures 3A and S3A) and al-
lowed the identification of three additional tumors included in
further gene expression analyses.
We correlated each of the four novel CNS tumor entities with
available basic clinical parameters (Figures 3C–3F). Noticeably,
the gender ratio was strongly shifted toward females in the
CNS HGNET-MN1 (p < 0.001), as also observed for ABM (Louis
et al., 2007). Patient age at diagnosis in CNS HGNET-MN1
was higher compared with other entities (p < 0.001). There
were no clear differences in tumor site of occurrence, although
occasional cerebellar location was restricted to tumors of the
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Figure 2. Molecular and Clinical Characteristics of Re-classified CNS-PNET Groups
(A–D) Molecular characteristics of CNS-PNETs from ETMR (A), AT/RT (B), HGGIDH, HGGK27, and HGGG34 (C), and HGGMYCN (D) DNA methylation clusters.
Detection and frequency of characteristic molecular alterations in each group is indicated. Representative copy-number profiles in (A), (B), and (D) depict genomic
gains (green dots) and losses (red dots) on individual chromosomes as indicated. FISH and IHC images in (A), (B), and (D) show representative tumor samples.
(E–H) Tumor location and age at diagnosis from ETMR (E), AT/RT (F), HGGIDH, HGGK27, and HGGG34 (G), and HGGMYCN (H) DNAmethylation clusters. Black bars
in age plots indicate the median. Numbers in brackets indicate group size with available data.
See also Figure S2 and Table S2.CNS HGNET-MN1 and CNS HGNET-BCOR entities. Infratento-
rial, non-cerebellar location was not associated with a
specific molecular CNS tumor entity. Surgical and pathological
reports of four CNS EFT-CIC tumors did not indicate meningeal
or osseous origin. Available survival data suggested differences
between the novel CNS tumor entities, with significantly
better overall survival observed for patients from the CNS
HGNET-MN1 compared to the CNS HGNET-BCOR entity
(Figure S3D).
Histopathology of New CNS Tumor Entities
Histopathological review was performed on 30 CNS NB-FOXR2,
14 CNS HGNET-BCOR, 10 CNS HGNET-MN1, and four CNSEFT-CIC tumors (Tables S2A–S2C). The CNS NB-FOXR2 entity
displayed embryonal architectural and cytological features
with a small-cell phenotype (Figures 4A–4C). Areas of differentia-
tion in the formof neuropil, neurocytic cells, or ganglion cellswere
observed in a high proportion of tumors (Figure 4C). Frequent
perivascular anuclear zones (‘‘vascular pseudorosettes’’), nu-
clear palisades, and Homer Wright rosettes were encountered
in individual samples (Figure S4A; Tables S2B and S2C). This
group encompassed tumors that would be classified as CNS
neuroblastoma or CNS ganglioneuroblastoma in the 2007 WHO
classification scheme (Louis et al., 2007) (Figures 4A–4C). CNS
NB-FOXR2 tumors nearly uniformly expressed OLIG2 and the
neuronal antigen synaptophysin (Figures S4A and S4B).Cell 164, 1060–1072, February 25, 2016 ª2016 Elsevier Inc. 1065
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Figure 3. Identification of New CNS Tumor Entities across Histologies
(A) Unsupervised clustering of DNA methylation patterns of 77 CNS-PNET samples alongside 159 reference samples and 59 additional samples representing
CNS tumors of varying histology using the 10,000 most variably methylated probes. Molecular subgroup assignment by DNA methylation (inner circle) or gene
expression patterns (middle circle) correspond to subgroup labels. Original tumor histology (outer circle) is depicted for tumors from new molecular CNS tumor
entities by colored bars as indicated.
(B) Composition of four new CNS tumor entities by histological diagnosis. Tumor histology is represented by colors as indicated.
(C–F) Clinical patient information for four novel CNS tumor entities CNSNB-FOXR2 (C), CNS EFT-CIC (D), CNS HGNET-MN1 (E), and CNSHGNET-BCOR (F). For
each entity, tumor location (left), age at diagnosis (middle), and gender distribution (right) is shown. Numbers in brackets indicate group size with available data.
See also Figure S3 and Table S3.The CNS EFT-CIC entity was also characterized by a small-
cell phenotype but with variable histology (Figures 4D–4F). The
tumor architecture included both alveolar and fascicular patterns
of growth. Although tumorswere uniformly high grade, this group
lacked defining histological features and failed to express
markers of differentiation.
The CNS HGNET-MN1 entity (Figures 4G–4I) consisted
of circumscribed high-grade tumors containing a mixture of
solid and pseudopapillary patterns. Dense pericellular hyalini-
zation was frequently present in this group. Some had the
typical pathology of the tumor termed astroblastoma (ABM)
in the current WHO classification system, whereas others
were harder to align with that diagnosis. The majority of
tumors (16/23) from our current collection histologically diag-1066 Cell 164, 1060–1072, February 25, 2016 ª2016 Elsevier Inc.nosed as ABM belonged to this molecular entity. Thus,
we consider it unlikely that there is an additional true ‘‘astro-
blastoma’’ entity other than the MN1-altered entity outlined
here.
The CNS HGNET-BCOR entity consisted of relatively com-
pact tumors with a combination of spindle to oval cells. They
often exhibited perivascular pseudorosettes, giving the tumors
an ependymoma-like appearance (Figures 4J–4L). Tumors
frequently demonstrated fibrillary processes, typical of glial dif-
ferentiation, and only in rare instances exhibited true embryonal
morphology.
Tumors from CNS HGNET-MN1 and CNS HGNET-BCOR en-
tities frequently expressed GFAP, but neuronal antigen expres-
sion was either focal or absent. In comparison, mitotic counts
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Figure 4. Histopathological Patterns of New
CNS Tumor Entities
(A–C) The CNS NB-FOXR2 entity was character-
ized by uniform round embryonal cells withminimal
cytological pleomorphism. Nuclear palisades and
neurocytic differentiation were frequently encoun-
tered.
(D–F) CNS EFT-CIC tumors were composed of
small monotonous cells. The tumor architecture
was variable and included fascicular and alveolar
growth. Select examples demonstrated a spindle
cell phenotype.
(G–I) CNSHGNET-MN1 tumors were composed of
monotonous neuroepithelial cells with oval forms.
Pseudopapillary architecture and dense stromal
hyalinization was often encountered.
(J–L) The CNS HGNET-BCOR entity was charac-
terized by oval to elongated cells. Perivascular
anuclear zones were often present and glial fibril-
lary processes were typical.
Scale bars represent 50 mm.
See also Figure S4.were high for CNS NB-FOXR2 and CNS EFT-CIC tumors, but
lower for the other two entities (Figure S4C).
Genetic Alterations Define New CNS Tumor Entities
For each of the four new CNS tumor entities, we next inspected
copy-number profiles derived from DNA methylation arrays.
Gain of chromosome arm 1q was characteristic for the CNS
NB-FOXR2 entity (43/44, 98%; p < 0.001) (Figure S5A). Further
broad aberrations included loss of 16q in CNS NB-FOXR2 (21/
42, 50%) and CNS HGNET-MN1 (12/37, 32%), and gain of chro-
mosome 8 in CNSNB-FOXR2 (14/44, 32%), CNS EFT-CIC (3/13,
23%), and CNS HGNET-MN1 (6/38, 16%) tumors. Most tumors
from the CNS HGNET-BCOR entity displayed balanced copy-
number profiles. We only detected high-level focal oncogene
amplifications of MYC and CDK4, each in one CNS NB-FOXR2
sample, and EGFR and CDK4 in one CNS HGNET-MN1 sample
(Table S4). Homozygous deletions ofCDKN2Awere found in two
CNS HGNET-BCOR and one CNS HGNET-MN1 tumors.
In order to identify genetic alterations that underlie each of the
four new, molecularly defined CNS tumor entities in greater
detail, we performed genome-wide DNA and RNA sequencing
of all cases with available fresh-frozen tissue (Table S4). As out-
lined below, we found that each entity was characterized by a
recurrent genetic alteration.
CNS Neuroblastoma with FOXR2 Activation
Genome-wide sequencing revealed complex inter- and intra-
chromosomal re-arrangements converging on forkhead box R2
(FOXR2) in 6/8 samples with available data, leading to increased
FOXR2 gene expression levels in CNS NB-FOXR2 tumorsCell 164, 1060–1072, Fcompared with other CNS tumor entities
(Figures 5A–5C). Three of the detected
events resulted in fusion transcripts re-
taining the full coding sequence of
FOXR2, with upstream non-coding exons
forming a novel transcript variant fused to
different fusion partners (Figures S5B andS5C). These included JMJD1C as a result of a complex inter-
chromosomal translocation involving chromosome 10, and
LOC550643 and JPX as products of tandem duplications on
chromosome X. These duplications were also detectable by
characteristic copy-number changes in three samples without
available sequencing data (Figure S5D). We further identified a
recurrent deletion between full-length FOXR2 and MAGEH1 in
two samples. Copy-number data indicated additional alterations
targeting the FOXR2 locus in seven samples (Figure S5D), with a
deletion reaching 500 kb upstream of FOXR2 as the most
frequent event (4/46, 9%), potentially fusing FOXR2 to the
MAGED2 gene.
Moreover, we identified a mitochondrial DNA insertion within
USP51 that led to the formation of a novel FOXR2 promoter (Fig-
ure S5E). Mitochondrial-nuclear genome fusions have been
recently reported to occur frequently in cancer (Ju et al., 2015),
but this is the first example in which such an event induces onco-
gene expression. Since FOXR2 is not expressed in other CNS
tumor types (Figure 5C) or normal brain tissues, these events
are suggestive of FOXR2 activation facilitated by promoters of
active genes (Figure S5F), thus instigating oncogenic activity
(Rahrmann et al., 2013). One exceptional tumor that did not
show elevated gene expression of FOXR2 was the only one to
harbor a focal amplification of MYC, resulting in upregulated
MYC gene expression compared with FOXR2-activated tumors
(Figure S5F). The FOXR2 homolog FOXR1 is recurrently acti-
vated in peripheral neuroblastoma counterparts by intrachromo-
somal deletion/fusion events, resulting in overexpression of
fusion transcripts (Santo et al., 2012).ebruary 25, 2016 ª2016 Elsevier Inc. 1067
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Figure 5. Recurrent Molecular Alterations in the CNS NB-FOXR2 Entity
(A) Schematic representation depicting chromosomal location, wild-type RNA transcripts, and exon structures resulting from an exemplary genetic alteration
affecting the FOXR2 gene.
(B) Frequency of FOXR2 re-arrangements identified by RNA/DNA sequencing or copy-number data.
(C) Gene expression levels of FOXR2 in various CNS tumor entities.
See also Figure S5 and Table S4.CNS Ewing Sarcoma Family Tumor with CIC Alteration
In three tumors analyzed by RNA sequencing we detected an
interchromosomal gene fusion between capicua transcriptional
repressor (CIC, located on chromosome 19q13.2) and NUT
midline carcinoma, family member 1 (NUTM1, located on chro-
mosome 15q14) in two samples (Figures 6A, 6B, and S6A),
while the third harbored a frameshift deletion in CIC (exon6:
c.902delC:p.S301fs). Both fusion events fused exon 16 of
CIC in-frame to exon 4 of NUTM1, retaining the DNA-binding
high mobility group (HMG) box domain of CIC. Using a CIC
break-apart FISH probe, we identified CIC re-arrangements in
8/9 samples, including one of the tumors analyzed by RNA
sequencing (Figures 6B and S6B), while the FISH-negative tu-
mor carried the CIC frameshift deletion. Gene expression
data indicated transcriptional upregulation of fusion partner
NUTM1 in this group compared with all other samples (Fig-
ure 6C). Consequently, those tumors showed strong reactivity
when investigated for NUTM1 protein expression by immuno-
histochemistry, while no tumors from any other entity stained
positive (Figures 6B, S4A, and S4B). On the basis of CIC fu-
sions present in subgroups of pediatric primitive round cell sar-
comas (Haidar et al., 2015) and their distinct transcriptional
signature (Specht et al., 2014), we analyzed CNS EFT-CIC tu-
mors for similar gene expression patterns. As observed in pe-
ripheral EFT, among the genes specifically upregulated in this
group were members of the ETS transcription factor family,
including ETV1, ETV4, ETV5, FLI1, and ETS1 (Figure S6C).
Oncogenic re-arrangements of NUTM1 are a defining genetic
feature of NUT midline carcinomas (NMC), in most cases
involving bromodomain-containing protein 4 (BRD4) (French,
2014). We hypothesize a molecular mode of action of CIC-
NUTM1 fusions in which specific CIC target genes are tran-
scriptionally activated by the NUTM1 moiety via the recruitment
of histone acetyl transferases, similar to a model of how BRD4-
NUTM1 might block differentiation in NMC (French, 2014). As
this may lead to global hypoacetylation, these findings provide
a rationale for testing the efficacy of epigenetically active drugs
in this tumor entity.1068 Cell 164, 1060–1072, February 25, 2016 ª2016 Elsevier Inc.CNS High-Grade Neuroepithelial Tumor with MN1
Alteration
We identified interchromosomal gene fusions betweenmeningi-
oma (disrupted in balanced translocation) 1 (MN1, 22q12.3) and
BEN domain containing 2 (BEND2, Xp22.13) in three samples,
and MN1 and CXXC-type zinc-finger protein 5 (CXXC5, 5q31.2)
in one sample (Figures 6D, 6E, and S6D) from RNA sequencing
data of four tumors. Using an MN1 break-apart FISH probe,
MN1 re-arrangement was confirmed in three of the tumors with
RNA sequencing data and nine additional tumors from the
CNS HGNET-MN1 entity (Figures 6E and S6E). High-level gene
expression of the fusion partner BEND2 was observed specif-
ically in CNS HGNET-MN1 tumors, while being absent in other
CNS tumor types (Figure 6F). BEND2 immunohistochemistry
failed to give reliable results due to non-specific staining with
available antibodies. In the tumor with MN1-CXXC5 fusion,
CXXC5 but not BEND2, was expressed at high levels (data not
shown). A smaller set of five samples, including the tumor
harboring the MN1-CXXC5 fusion, formed a distinctly separate
cluster, while all three tumors harboring an MN1-BEND2 fusion
were found in a larger homogenous cluster, potentially indicating
differences in underlying biology depending on the MN1 fusion
partner (Figures 3A and S3A). The gender bias was even more
striking in the two separated clusters (male:female ratio: 2:32,
p < 0.001; and 4:1, respectively). Fused to BEND2, the encoded
chimeric protein combines the transactivating domains of MN1
and the two BEN domains in the C terminus of BEND2, which
have been suggested to mediate protein-DNA and protein-pro-
tein interactions during chromatin organization and transcription
(Abhiman et al., 2008). In myeloid leukemia, frequently occurring
MN1-TEL fusion proteins act as transcription factors with trans-
forming activity both via targeting TEL binding sites (Buijs et al.,
2000) and a dominant-negative effect on wild-type MN1 (van
Wely et al., 2007).
CNS High-Grade Neuroepithelial Tumor with BCOR
Alteration
DNA andRNA sequencing revealed in-frame internal tandem du-
plications of the BCL6 corepressor (BCOR) in 10/10 (100%)
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Figure 6. Recurrent Molecular Alterations in CNS EFT-CIC, CNS HGNET-MN1, and CNS HGNET-BCOR Entities
(A–I) Schematic representation, frequency, and transcriptomic effects of recurrent molecular alterations found in tumors from the CNS EFT-CIC (A–C), CNS
HGNET-MN1 (D–F), and CNS HGNET-BCOR (G–I) entities. Schematics in (A), (D), and (G) depict chromosomal location, wild-type RNA transcripts, and exon
structures resulting from recurrent alterations. The frequencies of the respective events detected by different methods are depicted in (B), (E), and (H). Gene
expression levels of NUTM1, BEND2, and BCOR across various CNS tumor entities are displayed in (C), (F), and (I).
See also Figure S6 and Table S4.samples (Figures 6G, 6H, and S6F). The duplicated region in
exon 15 of BCORwas identical with that of BCOR tandem dupli-
cations recently described in clear cell sarcomas of the kidney
(Ueno-Yokohata et al., 2015) (Figure S6G). One additional tumor
harbored an intragenic in-frame deletion in BCOR fusing the pre-
vious exon directly to the sequence duplicated in the other sam-
ples (Figure S6F), while two more tumors from that entity carried
BCOR frameshift mutations. Duplications in BCOR were de-
tected by targeted PCR in five additional tumors (Figures 6H
and S6G). Activation of the WNT signaling pathway as indicated
by nuclear beta-catenin immunoreactivity was observed in 11/14
samples (79%) (Figures S4A and S4B). Gene expression of
BCOR was found at higher levels in CNS HGNET-BCOR tumors
than in most other CNS tumor types (Figure 6I). High expression
of altered BCOR transcripts in CNS HGNET-BCOR tumors sug-
gests a mechanism different from BCOR loss-of-function muta-
tions reported in other malignancies, such as medulloblastoma
(Jones et al., 2012; Pugh et al., 2012).Differential Pathway Activation in New CNS Tumor
Entities
Array-based gene expression analyses of tumors from the four
new entities (n = 34) identified many genes (range: 435–2,880)
as significantly (adj. p < 0.001) differentially expressed between
one versus the other three entities (Table S5). Subsets of these
genes, which frequently included transcription factors and po-
tential drug targets, showed upregulated expression within the
new entities (Figures 7A and S7A), suggesting activation of spe-
cific pathways or transcriptional networks (Figure S7B), and
were also often not expressed in other CNS tumor entities (Fig-
ure 7B). Gene-ranked pathway enrichment analysis (Reimand
et al., 2011) of entity-specific genes relative to non-neoplastic
brain tissues indicated several general and specific neuronal
developmental processes being activated similarly in each of
the four entities, but also identified deregulated processes and
pathwaysmore unique to one ormore of the entities (Figure S7C;
Tables S6A–S6D).Cell 164, 1060–1072, February 25, 2016 ª2016 Elsevier Inc. 1069
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Figure 7. Transcriptional Profiling of New
CNS Tumor Entities
(A) Heatmap representing the expression levels of
the ten most significantly differentially upregulated
genes comparing one new CNS tumor entity
versus the three others. Each column represents
one sample, and each lane represents one gene.
Gene expression levels are represented by a color
scale as indicated.
(B) Individually selected marker genes specifically
upregulated in one of the new CNS tumor entities
compared with other CNS tumor entities as indi-
cated.
See also Figure S7 and Tables S5 and S6.DISCUSSION
Our study demonstrates that the embryonal histology of CNS-
PNETs does not correspond to a homogeneous molecular class
and suggests that a majority of tumors designated CNS-PNET
represent morphological variants of other histologically and
molecularly defined diagnostic entities. While a subset of tumors
diagnosed as CNS-PNET were questionable or inaccurate diag-
noses upon expert review, a high proportion of tumors demon-
strated ambiguous small-cell morphology that was difficult to
classify on histology alone, highlighting the diagnostic necessity
of utilizing established molecular markers.
Our study also led to the identification of four new molecularly
defined CNS tumor entities. The entity designated ‘‘CNS neuro-
blastoma with FOXR2 activation’’ consisted of a relatively pure
population of CNS-PNET and was enriched for CNS-PNET vari-
ants CNS neuroblastoma and ganglioneuroblastoma. This entity
therefore clarifies the molecular underpinnings of histopatholog-
ical CNS-PNET variants into two primary entities, namely, ETMR
(which accounts for the previously described ETANTR, ME, and
EB) and CNS NB-FOXR2. We have further defined three addi-
tional molecular entities among pediatric CNS tumors, of which
one entity, CNS HGNET-MN1, incorporates astroblastomas,
while CNSEFT-CIC andCNSHGNET-BCOR represent novel en-
tities displaying pathological overlap with CNS-PNET and other
histological entities.
A minority of CNS-PNETs failed to classify into a specific sub-
group, therefore representing a group we currently consider as
‘‘CNS embryonal tumors, NOS.’’ However, as international ini-1070 Cell 164, 1060–1072, February 25, 2016 ª2016 Elsevier Inc.tiatives accumulate larger tumor series,
our approach has potential to expand
the molecular classification of malignant
brain tumors, pushing the limits of what
is recognized as a bona fide entity.
In conclusion, our findings reinforce the
importance of incorporating molecular in-
formation into the next revision of the
WHO classification of CNS tumors (Louis
et al., 2014) and warrant a replacement of
the term ‘‘CNS-PNET’’ with biologically
specific designations. Our study provides
an innovative framework for improvingdiagnostic accuracy and prognostication in malignant CNS tu-
mors. The approach is amenable to retrospective analyses of pa-
tients treated with current regimens and will facilitate the design
of more meaningful clinical trials for patients with malignant brain
tumors.EXPERIMENTAL PROCEDURES
Tumor samples and clinical data were collected at the DKFZ (Heidelberg,
Germany) and at the St. Jude Children’s Research Hospital (Memphis) in
accordance with research ethics board approval from both institutes. Addi-
tional tumor samples and clinical data were provided by collaborating centers
world-wide. Clinical patient details can be found in Tables S1A and S3. An
overview of all CNS-PNET and other CNS tumor samples included in various
analyses is given within the Supplemental Experimental Procedures. Inclusion
criteria for CNS-PNET samples comprised an institutional diagnosis of ‘‘CNS-
PNET’’ (excluding medulloblastoma) and sufficient high-quality DNA for
methylation profiling. Wherever possible, H&E-stained formalin-fixed
paraffin-embedded (FFPE) sections from CNS-PNET and additional CNS tu-
mor samples were reviewed by experienced neuropathologists (A.K.,
D.W.E., B.A.O., D.C.; n = 151; see Table S2).
DNA methylation profiling of CNS-PNET and reference samples was
performed from both fresh-frozen and FFPE tissue using the Infinium Human-
Methylation450 BeadChip Array (450k array) in accordance with the manufac-
turer’s instructions (Illumina). For unsupervised hierarchical clustering of CNS-
PNETand reference samples,weselected the 10,000most variablymethylated
probes across the dataset. Copy-number variation (CNV) analysis from 450k
methylation array data was performed using the conumee Bioconductor pack-
age (v.1.0.0). Scoring of focal amplifications and deletions and chromosomal
gains and losses was performed by manual inspection of each profile.
Samples for which RNA of sufficient quantity and quality was available were
analyzed on the Affymetrix GeneChip Human Genome U133 Plus (v.2.0) Array
(Affymetrix). Sample library preparation, hybridization, and quality control were
performed in accordance with the manufacturer’s protocols.
Next-generation DNA and RNA sequencing was performed using Illumina
technologies as previously described (Jones et al., 2012). In addition to auto-
mated detection of alterations, candidate genes and their 30 and 50 intergenic
neighborhood were manually investigated using the Integrative Genomics
Viewer (IGV) (Robinson et al., 2011) for any breakpoints.
A detailed description of each analysis presented in this study can be found
within the Supplemental Experimental Procedures.
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